Matthew R. Bull
Auckland, AUK 1142, New Zealand
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Design and Biological Evaluation of Piperazine-Bearing Nitrobenzamide Hypoxia/GDEPT Prodrugs: The Discovery of CP-506.
Journal: ACS medicinal chemistry letters
Published: July 24, 2023
Preclinical Activity and Pharmacokinetic/Pharmacodynamic Relationship for a Series of Novel Benzenesulfonamide Perforin Inhibitors.
Journal: ACS pharmacology & translational science
Published: January 20, 2022
Interrogation of the Structure-Activity Relationship of a Lipophilic Nitroaromatic Prodrug Series Designed for Cancer Gene Therapy Applications.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: December 16, 2021
Restoring Tumour Selectivity of the Bioreductive Prodrug PR-104 by Developing an Analogue Resistant to Aerobic Metabolism by Human Aldo-Keto Reductase 1C3.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: November 01, 2021
Tissue Pharmacokinetic Properties and Bystander Potential of Hypoxia-Activated Prodrug CP-506 by Agent-Based Modelling.
Journal: Frontiers in pharmacology
Published: October 28, 2021
Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506.
Journal: Molecular cancer therapeutics
Published: May 05, 2021
Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 08, 2020
Inhibition of the Cytolytic Protein Perforin Prevents Rejection of Transplanted Bone Marrow Stem Cells in Vivo.
Journal: Journal of medicinal chemistry
Published: September 19, 2019
Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy.
Journal: Biochemical pharmacology
Published: May 25, 2016
The preclinical pharmacokinetic disposition of a series of perforin-inhibitors as potential immunosuppressive agents.
Journal: European journal of drug metabolism and pharmacokinetics
Published: May 18, 2014
Exploration of a series of 5-arylidene-2-thioxoimidazolidin-4-ones as inhibitors of the cytolytic protein perforin.
Journal: Journal of medicinal chemistry
Published: November 08, 2013
Showing 1-11 of 11
Last Updated: 09/26/2026